Colin Sandercock - Sep 26, 2025 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
SVP, GENERAL COUNSEL
Signature
/s/ Colin Sandercock
Stock symbol
CUE
Transactions as of
Sep 26, 2025
Transactions value $
$0
Form type
4
Date filed
12/5/2025, 06:54 PM
Previous filing
Mar 25, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Sandercock Colin SVP, GENERAL COUNSEL C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON /s/ Colin Sandercock 2025-12-05 0001724870

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Stock Option (right to buy) Award $0 +30K $0.00 30K Sep 26, 2025 Common Stock 30K $0.70 Direct F1
transaction CUE Stock Option (right to buy) Award $0 +70K $0.00 70K Dec 3, 2025 Common Stock 70K $0.70 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 24, 2024 the Reporting Person was granted an option with vesting subject to the satisfaction of performance-based vesting criteria. The performance-based vesting criteria for these shares was deemed satisfied or waived on September 26, 2025 and these shares underlying the option vested.
F2 On July 24, 2024 the Reporting Person was granted an option with vesting subject to the satisfaction of performance-based vesting criteria. The performance-based vesting criteria for these shares was deemed satisfied or waived on December 3, 2025 and these shares underlying the option vested.